Markets.com Logo
markets.com

EXEL

$--
--%
1d
1w
1m

Analysis and statistics

  • Open
    37.9802$
  • Previous Close
    38.8168$
  • 52 Week Change
    24.50$
  • Day Range
    -0.84$
  • 52 Week High/Low
    25.12$ - 49.62$
  • Dividend Per Share
    --
  • Market cap
    10 421 M$
  • EPS
    0.75
  • Beta
    0.288
  • Volume
    --

About

EXEL.US represents the common stock of Exelixis, Inc., a biotechnology company focused on discovering, developing, and commercializing new medicines for cancer treatment. Their primary focus is on kinase inhibitors that target key signaling pathways involved in tumor growth and metastasis. Their key product is CABOMETYX (cabozantinib), approved for various indications including renal cell carcinoma and hepatocellular carcinoma.
markets.com
Dogecoin Price Forecast 2026–2030: Can DOGE Reach $1?

Dogecoin Price Forecast 2026–2030: Can DOGE Reach $1?

Julian Parker|--
Solana Price Prediction 2026, 2030 & 2040: How High Can SOL Go?

Solana Price Prediction 2026, 2030 & 2040: How High Can SOL Go?

Daniel Carter|--
Nvidia Q2 Earnings Preview: Can $92 Billion Revenue End NVDA’s Seven-Day Slide?

Nvidia Q2 Earnings Preview: Can $92 Billion Revenue End NVDA’s Seven-Day Slide?

Julian Parker|--
Ethereum (ETH) Price Prediction 2026-2030: Can ETH Break $3,000 After a 33% Weekly Rally?

Ethereum (ETH) Price Prediction 2026-2030: Can ETH Break $3,000 After a 33% Weekly Rally?

Julian Parker|--
Coinbase Stock Forecast 2026–2030: Can COIN Recover as Bitcoin Nears $80,000?

Coinbase Stock Forecast 2026–2030: Can COIN Recover as Bitcoin Nears $80,000?

Julian Parker|--
Cryptos shine again, USD on the edge

Cryptos shine again, USD on the edge

Darius Anucauskas|--
Samsung Stock Forecast: Can AI Memory Demand Offset the Latest Sell-Off?

Samsung Stock Forecast: Can AI Memory Demand Offset the Latest Sell-Off?

Julian Parker|--

Factors

Drug Development Success: Positive clinical trial results for Exelixis' drugs, especially cabozantinib, drive price up. Failures lead to declines.

Regulatory Approvals: FDA approval of new indications or drugs significantly boosts investor confidence and the stock price.

Competition: Emergence of competing therapies or drugs can negatively impact market share and reduce the stock price.

Market Conditions: General market trends, economic downturns, and sector-specific sentiments (biotech) influence EXEL.US.

Financial Performance: Strong revenue growth, profitability, and positive earnings reports generally increase the stock price.

People Also Watch

Latest news

Bitcoin Price Surges Past $80,000 as ‘Debasement Trade’ Returns

Bitcoin Price Surges Past $80,000 as ‘Debasement Trade’ Returns

Julian Parker|--
Nvidia Stock Rises 2.19% as $280bn Earnings Swing Looms

Nvidia Stock Rises 2.19% as $280bn Earnings Swing Looms

Julian Parker|--
Oil Price Today: WTI Falls 2.6% to $80.20 on Hormuz Deal Hopes

Oil Price Today: WTI Falls 2.6% to $80.20 on Hormuz Deal Hopes

Julian Parker|--

Latest Education Articles

Top Meme Coins to Watch in 2026: A Trader’s Guide

Top Meme Coins to Watch in 2026: A Trader’s Guide

Julian Parker|--
XAU/USD Trading Hours in Dubai: When Does the Gold Market Open?

XAU/USD Trading Hours in Dubai: When Does the Gold Market Open?

Daniel Carter|--
How to Trade Gold CFDs: A Beginner’s Guide to XAU/USD Trading

How to Trade Gold CFDs: A Beginner’s Guide to XAU/USD Trading

Daniel Carter|--
Recommended Topics
markets.com